Admin-Core-001

管理核心-001

• 批准号: 10942885
• 负责人: Boyi Gan
• 金额: $ 18.23万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10942885
• 关键词: Achievement; Administrative Supplement; Advisory Committees; Basic Science; Benchmarking; Cancer Patient; Clinical; Cloning; Collaborations; Combined Modality Therapy; Communication; Data; Development; Direct Costs; Doctor of Philosophy; Ensure; Esophageal Adenocarcinoma; Evaluation; Faculty; Funding; Genomics; Goals; Guidelines; Human; Hypoxia; Image; Imaging Device; Immunotherapy; Infrastructure; Institution; Intellectual Property; Iron; Knowledge; Leadership; Malignant neoplasm of esophagus; Malignant neoplasm of lung; Measures; Metabolic; Mus; Myeloid Cells; National Cancer Institute; Office of Administrative Management; Patients; Performance; Policies; Pre-Clinical Model; Principal Investigator; Process; Production; Progress Reports; Radiation; Radiation therapy; Radiation-Sensitizing Agents; Reporter Genes; Research; Research Project Grants; Resistance; Resource Sharing; Resources; Risk; Role; Sampling; Students; Technology; Testing; Therapeutic Agents; Training; Transfection; Transgenic Organisms; Translating; Translational Research; Wages; Work; Xenograft Model; anticancer research; cancer cell; cancer type; chemoradiation; cohort; conflict resolution; data management; data sharing; esophageal cancer patient; interest; meetings; member; molecular imaging; neoplastic cell; novel therapeutics; outreach; peer; programs; radiation resistance; stable cell line; standard of care; therapy resistant; tool; tumor; tumor growth; tumor hypoxia; web site

ADMINISTRATIVE CORE – SUMMARY The proposed Acquired Resistance to Therapy and Iron (ARTI) Center is focused on the role of ferroptosis in acquired resistance to radiation therapy. Radiation therapy is used to treat approximately 50% of cancer patients and is standard of care treatment for lung cancer and esophageal cancer patients. The ARTI Center will focus on these cancer types and comprise three research projects. Project 1 will focus on identifying the mechanisms of ferroptosis in acquired resistance to radiation therapy and testing ferroptosis inducers (FINs) as radiosensitizers. Project 2 will focus on determining whether hypoxia-induced resistance to ferroptosis contributes to acquired tumor resistance to radiation therapy and whether FINs re-sensitize hypoxic tumor cells to radiation treatment. Project 3 will focus on understanding the role of genomic and microenvironment factors in acquired resistance to ferroptosis to chemoradiation in esophageal adenocarcinoma. The three research projects will be supported by one shared Molecular Imaging Core (MIC), which will provide imaging tools and analyses for measuring tumor growth, assessing the ability to overcome acquired radiation resistance using combination therapies (e.g., FINs with radiation therapy or immunotherapy), identifying intratumoral hypoxic regions, and evaluating myeloid cell expansion in conferring ferroptosis resistance to chemoradiation therapy. To support the MIC and these three projects, the Administrative Core (AC) will be established as part of the ARTI Center infrastructure that will support, coordinate, and facilitate all activities aimed at achieving and evaluating milestones across the projects and core. The AC will establish and maintain engagement and communication among ARTI Center and ARTNet members and program officials in Aim 1. In Aim 2, the AC will facilitate ARTI Center evaluation, support the timely and quality development and submission of progress reports, and maintain proper and transparent stewardship of funds. The AC will develop and implement an internal solicitation and prioritization process for Pilot and Trans-Network Projects in Aim 3. In Aim 4, the AC will serve as the central infrastructure to build a website and manage data, materials, resources, conflict resolution, and issues of intellectual property for technologies and tools. The multiple Principal Investigators (mPIs) of the ARTI Center, Boyi Gan, PhD and Albert Koong, MD, PhD, will serve as AC Co-Leaders. Under their leadership, the AC will be able to leverage institutional and divisional resources; to establish and maintain an ARTI Center Advisory Committee; to encourage the development of junior faculty, trainees, and students in cancer research; to promote collaborations across ARTNet; and to ensure abidance by the ARTNet governance and resource and data sharing policies. Overall, the AC will be the central juncture for the ARTI Center to integrate with other ARTNet centers as well as other National Cancer Institute-funded programs and initiatives.

行政核心 - 总结所提出的对治疗和铁（ARTI）中心的抵抗力的重点是螺栓杀伤在获得放射治疗的耐药性中的作用。放射疗法用于治疗约50％的癌症患者，是肺癌和食管癌患者的护理标准治疗。 ARTI中心将专注于这些癌症类型，并完成三个研究项目。项目1将着重于确定对放射疗法的耐药性和测试铁铁蛋白诱导剂（FIN）作为放射增敏剂的抗性机制。项目2将重点侧重于确定缺氧诱导的对铁凋亡的耐药性是否有助于获得放射治疗的肿瘤耐药性，以及FINS是否会重新敏感的缺氧肿瘤细胞对放射治疗。项目3将集中于了解基因组和微环境因素在获得对食管腺癌化学糖尿基化化疗的耐药性中的作用。 The three research projects will be supported by one shared Molecular Imaging Core (MIC), which will provide imaging tools and analyses for measuring tumor growth, assessing the ability to overcome acquired radiation resistance using combination therapies (e.g., FINs with radiation therapy or immunotherapy), identifying intratumoral hypoxic regions, and evaluating myeloid cell expansion in conference ferroptosis resistance to chemoradiation therapy.为了支持麦克风和这三个项目，将建立行政核心（AC）作为ARTI中心基础设施的一部分，该基础设施将支持，协调和促进旨在实现和评估整个项目和核心里程碑的所有活动。 AC将在AIM 1中建立和维持ARTNET成员和计划官员之间的参与和沟通。在AIM 2中，AC将促进ARTI中心的评估，支持及时，质量发展和提交进度报告，并维持适当和透明的资金管理。 AC将在AIM 3中为试点和跨性网络项目开发并实施内部招标和优先级序列化过程。在AIM 4中，AC将作为构建网站并管理技术和工具知识产权问题的数据，材料，资源，解决冲突以及知识产权问题的中心基础架构。 Arti中心的多个主要研究人员（MPI），博士博士和医学博士Albert Koong博士将担任AC共同领导者。在他们的领导下，AC将能够利用机构和分区资源；建立和维护ARTI中心咨询委员会；鼓励开发癌症研究的初级教师，学员和学生；促进整个Artnet的合作；并确保ARTNET治理，资源和数据共享政策的余地。总体而言，AC将是ARTI中心与其他Artnet中心以及其他国家癌症研究所资助的计划和计划的中心关头。